HER2-targeted therapies hold promise for biliary tract cancers, where HER2 expression and amplification rates are notably high at 23–32% and 17–23%, respectively [4], with a mutation rate of 6.2% according to meta-analyses [80]. Here, ERBB2 is linked to biliary tract neoplasm.